# Elite Pharmaceuticals Inc /NV/ > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Elite Pharmaceuticals Inc /NV/). ## Overview Elite Pharmaceuticals, Inc. develops, manufactures, and commercializes generic and specialty pharmaceutical products, with a focus on controlled-release and abuse-deterrent formulations. The company also relies on licensing, marketing, and distribution arrangements, which means a meaningful part of its business depends on partners, a small number of products, and a concentrated customer base. ## Products & services • Generic pharmaceutical products • Controlled-release formulations • Abuse-deterrent opioid products • Product development and NDA pipeline • Manufacturing fees and license-based commercialization - **Generic pharmaceuticals** (55%) — Approved generic drug products sold through wholesalers, pharmacies, and other trade channels. - **Controlled-release formulations** (20%) — Extended-release dosage forms designed to deliver active ingredients over time. - **Abuse-deterrent products** (10%) — Products such as SequestOx™ intended to reduce abuse potential in opioid formulations. - **Manufacturing and license revenue** (15%) — Revenue earned through manufacturing fees, profit splits, and commercialization agreements. - Generic pharmaceutical products - Controlled-release formulations - Abuse-deterrent opioid products - Product development and NDA pipeline - Manufacturing fees and license-based commercialization ## Customers Elite sells primarily into a concentrated pharmaceutical channel rather than directly to end consumers. Its customers include wholesalers, retail drug chains, managed care organizations, group purchasing organizations, and marketing/license partners that buy products or commercial rights because they need low-cost generic supply and specialized formulations. The company also depends on a small number of large customers, making order timing and purchasing patterns especially important. - **Wholesalers and distributors** (primary) — Buy generic products in bulk for redistribution to pharmacies and other end customers; they matter because they control access to large downstream demand. - **Retail drug chains** (primary) — Purchase products through negotiated contracts and influence pricing through consolidation and buying leverage. - **Managed care organizations and insurers** (primary) — Shape demand by steering utilization toward lower-cost generics and by pressuring pricing and rebates. - **Group purchasing organizations and hospitals** (secondary) — Buy through contract channels and drive chargebacks, rebates, and price concessions. - **Collaborators and licensees** (secondary) — Commercialize or distribute selected products and share economics with Elite under licensing arrangements. - Wholesalers buying generic drugs for downstream pharmacy distribution - Retail drug chains seeking low-cost, contract-priced supply - Managed care organizations and insurers negotiating lower drug costs - Group purchasing organizations and hospital buyers - Marketing and licensing partners commercializing Elite products ## Geography Elite is a U.S.-based pharmaceutical company, and the available filings emphasize domestic regulatory, reimbursement, and distribution exposure. The business is tied to U.S. wholesalers, pharmacies, managed care organizations, and FDA/DEA oversight, so the U.S. market is the key operating geography. No country-level revenue split was disclosed in the provided excerpts. - Headquartered in the United States - U.S. market is the core commercial and regulatory exposure - Sales depend on domestic wholesalers, chains, and managed care - FDA and DEA oversight are central to product approval and supply - No country-level revenue disclosure was provided in the excerpts ## Strategy Elite's strategy centers on developing and commercializing a small portfolio of differentiated generic and specialty products while expanding through collaborators and licensees. The company is also trying to manage pricing pressure by working with managed care and insurer channels, but its filings show that execution risk remains high because product launches, regulatory approvals, and partner commitment all matter to revenue realization. - **Develop and launch new products** (medium-term) — Future revenue depends on successful development, approval, and commercialization of product candidates. - **Expand commercialization through partners** (short-term) — Collaborators and licensees can extend market reach without requiring Elite to build a large direct sales force. - **Defend pricing and access in concentrated channels** (short-term) — Retail chains, wholesalers, and managed care organizations have significant bargaining power and can pressure margins. - Advance a small number of high-value product families - Commercialize through partners where direct scale is limited - Pursue generic launches and specialty formulations - Negotiate with payers to reduce generic purchasing incentives - Protect product economics against price competition and consolidation ## Risks Elite faces concentrated-product and concentrated-customer risk, which makes revenue vulnerable to the loss of a single product, customer, or partner. Its filings also highlight regulatory, manufacturing, and litigation risks typical of pharmaceuticals, including FDA/DEA constraints, supply interruptions at a sole facility, and patent or pricing disputes that can quickly affect commercialization and cash flow. - **Customer concentration** [high] — A small number of customers account for most revenue, so lost orders would quickly hit sales and cash flow. - **Product concentration** [high] — Revenue depends on a limited number of products, increasing sensitivity to competition, regulation, or supply issues. - **Regulatory approval and compliance** [high] — Pharmaceutical products require FDA and DEA approvals and ongoing compliance, which can delay launches or restrict supply. - **Manufacturing interruption** [high] — Operations at a sole facility create a single point of failure for production and fulfillment. - **Pricing and reimbursement pressure** [medium] — Consolidated wholesalers, chains, and managed care buyers can demand discounts and rebates. - **Litigation and IP disputes** [medium] — Generic and controlled-substance products face patent, fraud-and-abuse, and product liability claims. - Top four product families generated over 90% of allocated revenues - Six largest customers generated over 80% of revenues - Sole-facility disruption could materially interrupt supply - FDA/DEA actions can delay approvals or restrict active ingredients - Chargebacks, rebates, and returns can reduce realized revenue - Patent, IP, and at-risk launch disputes can create litigation exposure ## Accounting Elite's most important accounting judgments relate to revenue recognition and variable consideration, because reported revenue is reduced by chargebacks, rebates, discounts, returns, and government pricing programs. The company also relies on estimates for deferred tax assets and other balances, so changes in assumptions can materially affect earnings and asset values. - **Variable consideration in revenue recognition** — Can materially change quarterly and annual revenue - **Chargeback and rebate reserves** — Affects net sales and gross margin - **Deferred tax assets and valuation allowance** — Can affect tax expense and equity - **Estimates for legal and regulatory contingencies** — Can affect expenses and liabilities - Revenue is net of chargebacks, rebates, discounts, and returns - Reserve estimates can materially change reported revenue - Manufacturing fees and profit shares require judgment on variable consideration - Deferred tax asset realizability depends on valuation allowance estimates - Intangible asset and product-related judgments may affect asset values --- *Last updated: 2026-04-28T20:02:57.937638+00:00*